Current Atherosclerosis Reports

, Volume 13, Issue 4, pp 298–305 | Cite as

Impact of Hypertension on Stroke

Article

Abstract

Hypertension is the single most important risk factor for all types of stroke: ischemic stroke, intracerebral hemorrhage, and aneurysmal subarachnoid hemorrhage. Epidemiologic studies over the past 30 years have demonstrated a dramatic reduction in the incidence and mortality of all stroke types with good control of hypertension, and it appears that all effective antihypertensive agents have similar efficacy in their ability to reduce stroke risk. In addition, it appears that acute treatment of hypertension in the setting of intracerebral hemorrhage and subarachnoid hemorrhage is beneficial, but it is still uncertain in the setting of ischemic stroke what level of blood pressure will result in the best possible outcome.

Keywords

Stroke Hypertension Intracerebral hemorrhage Subarachnoid hemorrhage Brain aneurysms 

Notes

Disclosure

The authors report no potential conflicts of interest relevant to this article.

References

Papers of particular interest, published recently, have been highlighted as: •• Of major importance

  1. 1.
    Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the joint national committee on prevention, detection, evaluation and treatment of high blood pressure: the JNC 7 report. JAMA. 2003;289:2560–72.PubMedCrossRefGoogle Scholar
  2. 2.
    •• Gillepsie C, Kuklina EV, Briss PA et al. Vital signs: prevalence, treatment, and control of hypertension—United States, 1999–2002 and 2005–2008. Morbidity and Mortality Weekly Report. 2011;60(4):102–8. This report contains the most recent population-based data regarding the prevalence and treatment of hypertension in the United States. It demonstrates how treatment has improved over the past several decades. Google Scholar
  3. 3.
    Rosamund W, Flegal K, Furie K, et al. Heart disease and stroke statistics – 2008 update: a report from the American Heart Association Statistics Subcommittee. Circulation. 2008;117(4):e25–146.CrossRefGoogle Scholar
  4. 4.
    Carandang R, Seshadri S, Beuser A, et al. Trends in incidence, lifetime risk severity and 30-day mortality of stroke over the last 50 years. JAMA. 2006;296(24):2939–46.PubMedCrossRefGoogle Scholar
  5. 5.
    Kannel WB, Wolf PA, Verter J, et al. Epidemiologic assessment of the role of blood pressure in stroke. The Framingham study. JAMA. 1970;214:301–10.PubMedCrossRefGoogle Scholar
  6. 6.
    Kannel WB, Wolf PA, McGee DL, et al. Systolic blood pressure, arterial rigidity, and risk of stroke. The Framingham study. JAMA. 1981;245:1225–9.PubMedCrossRefGoogle Scholar
  7. 7.
    Johansson BB. Hypertension mechanisms causing stroke. Clin Exp Pharmacol Physiol. 1999;7:563–5.CrossRefGoogle Scholar
  8. 8.
    Fisher C. Pathological observations in hypertensive cerebral hemorrhage. J Neuropath Exp Neurol. 1971;30:536–50.PubMedCrossRefGoogle Scholar
  9. 9.
    Heistad DD, Mayhan WG, Baumbach GL. Impaired dilation of cerebral arterioles in chronic hypertension. Blood Vessels. 1990;27:258–62.PubMedGoogle Scholar
  10. 10.
    Baumbach GL, Heistad DD. Cerebral circulation in chronic arterial hypertension. Hypertension. 12:89–95.Google Scholar
  11. 11.
    •• Rost NS, Rahman RM, Biffi A et al. White matter hyperintensity volume is increased in small vessel stroke subtypes. Neurology. 2010;75:1670–77. White matter hyperintensities, or leukoaraiosis, as diagnosed on MRI, have been noted as a risk factor for subsequent small vessel strokes as well as intracerebral hemorrhage, and have also been linked to chronic hypertension. PubMedCrossRefGoogle Scholar
  12. 12.
    O’Sullivan M. Leukoaraiosis. Pract Neurol. 2008;8:26–38.PubMedCrossRefGoogle Scholar
  13. 13.
    Berenstein A, Lasjaunias P, Ter Brugge KG. Aneurysmal vasculopathy: segmental vulnerability. In: Surgical neuroangiography. Berlin: Spring-Verlag; 2004. 375–80.Google Scholar
  14. 14.
    Ruland SD. Lifestyle modification, antihypertensives, and cholesterol-lowering medication for primary and secondary stroke prevention. Continuum. 11;4:47–60.Google Scholar
  15. 15.
    MacMahon S. Blood pressure and the prevention of stroke. J Hypertens. 1996;14 Suppl 6:S39–46.Google Scholar
  16. 16.
    PROGRESS Collaborative Group. Randomized trial of a perindopril-based blood pressure-lowering regimen amont 6105 individuals with previous stroke or transient ischemic attack. Lancet. 2001;358:1033–41.CrossRefGoogle Scholar
  17. 17.
    The Heart Outcome Prevention Evaluation Study Investigators. Effects of an angiotensin-converting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000;342:145–53.CrossRefGoogle Scholar
  18. 18.
    Dahlof B, Devereuz RB, for the LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan intervention for endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet. 2002;359:995–1003.PubMedCrossRefGoogle Scholar
  19. 19.
    ALHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic. The antihypertensive and lipid-lowering treatment to prevent heart attack trial. JAMA. 2002;288:2981–97.CrossRefGoogle Scholar
  20. 20.
    SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the systolic hypertension in the elderly program (SHEP). JAMA. 1991;265:3255–64.CrossRefGoogle Scholar
  21. 21.
    Yusuf S, Diener H-C, Sacco RL, for the Prevention Regimen for Effictively avoiding Second Strokes (PRoFESS) study group, et al. Telmisartan to prevent recurrent stroke and cardiovascular events. N Engl J Med. 2008;359(12):1225–37.PubMedCrossRefGoogle Scholar
  22. 22.
    Poulter NR, Wedel H, Dahlof B, for the ASCOT Investigators, et al. Role of blood pressure and other variables in the differential cardiovascular event rates noted in the Anglo-Scandinavian Cardiac Outomces Trial-Blod pressure lowering Arm (ASCOT-BPLA). Lancet. 2005;366:907–13.PubMedCrossRefGoogle Scholar
  23. 23.
    Staussen JA, Thijs L, Gasowski J, et al. Dihydropyridine calcium channel blockers for antihypertensive treatment in older patients—evidence from the Systolic Hypertension in Europe Trial. S Afr Med J. 2001;12:1060–8.Google Scholar
  24. 24.
    Black HR, Elliot WJ, Grandits G, et al. Results of the controlled Onset Verapamil Investigation of Cardiovascular Endpoints by geographic region (CONVINCE). J Hypertens. 2005;23(5):1099–106.PubMedCrossRefGoogle Scholar
  25. 25.
    Lindolm LH, Carlberg B, Samuelsson O. Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet. 2005;366:1545–53.CrossRefGoogle Scholar
  26. 26.
    Psaty BM, Lumley T, Furberg CD, et al. Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis. JAMA. 2003;289:2534–44.PubMedCrossRefGoogle Scholar
  27. 27.
    Wright JM, Musini VM. First line agents for hypertension. Cochrane Database Syst Rev. 2009:CD001841.Google Scholar
  28. 28.
    Adams H, Del Zoppo G, Alberts M, et al. Guidelines for the early management of adults with ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular and Interventional Radiology and Intervention Council and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: the American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists. Stroke. 2007;38:1655–711.PubMedCrossRefGoogle Scholar
  29. 29.
    International Stroke Trial Collaborative Group. The International Stroke Trial (IST): a randomized trial of aspirin, subcutaneous heparin, both, or neither among 19,435 patients with acute ischemic stroke. Lancet. 1997;349:1569–81.CrossRefGoogle Scholar
  30. 30.
    Leonardi-Bee J, Bath PM, Phillips SJ, FRCP for the IST Collaborative Group, et al. Blood pressure and clinical outcomes in the International Stroke Trial. Stroke. 2002;33:1315–20.PubMedCrossRefGoogle Scholar
  31. 31.
    The National Institute of Neurological Disorders and Stroke rt-PA Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1995;333:1581–7.CrossRefGoogle Scholar
  32. 32.
    •• Geeganage C, Tracy M, England T, et al. for TIAST Investigators. Relationship between baseline blood pressure parameters (including mean pressure, pulse pressure, and variability) and early outcome after stroke. Stroke. 2011;42:491–93. The TIAST trial showed that early death and neurologic deterioration, as well as recurrent stroke, were independently associated with baseline high systolic BP, mean arterial BP, pulse pressure, and blood pressure variability. PubMedCrossRefGoogle Scholar
  33. 33.
    Ahmed J, Nassman P, Wahlgren NG. Effect of intravenous nimodipine on blood pressure and outcome after acute ischemic stroke. Stroke. 2000;31:1250.PubMedCrossRefGoogle Scholar
  34. 34.
    Schrader J, Luders S, Kulschewski A, on behlaf of the ACCESS Study Group, et al. The ACCESS study: evaluation of acute candesartan cilexetil therapy in stroke survivors. Stroke. 2003;34:1699–703.PubMedCrossRefGoogle Scholar
  35. 35.
    •• Sandset EC, Bath PW, Boysen G, et al. on behalf of the SCAST Study Group. The angiotensin-receptor blocker candesartan for treatment of acute stroke (SCAST): a randomized, placebo-controlled, double-blind trial. Lancet. 2011;371:741–50. In this trial, candesartan, compared with placebo, resulted in a lower BP in the acute setting of ischemic stroke, but this did not result in reduced mortality, or recurrent stroke risk. CrossRefGoogle Scholar
  36. 36.
    Shin HK, Nishimura M, Jones PB, et al. Mild induced hypertension improves blood flow and oxygen metabolism in transient focal cerebral ischemia.Google Scholar
  37. 37.
    Wise G, Sutter R, Burhkolder J. The treatment of brain ischemia with vasopressor drugs. Stroke. 1972;3:135–40.PubMedCrossRefGoogle Scholar
  38. 38.
    Hillis AE, Ulatowski JA, Barker PB, et al. A pilot randomized trial of induced blod pressure elevation: effects of function and focal perfusion in acute and subacute stroke. Cerebrovasc Dis. 2003;16:236–46.PubMedCrossRefGoogle Scholar
  39. 39.
    Marzan AS, Hungerbuhler JH, Studer A, et al. Feasibility and safety of norepinephrine induced arterial hypertension in acute ischemic stroke. Neurology. 2004;62:1193–5.PubMedGoogle Scholar
  40. 40.
    Chimowitz MI, Lynn MJ, Howlett-Smith H, et al. Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis. N Engl J Med. 2005;352:1305–16.PubMedCrossRefGoogle Scholar
  41. 41.
    Brott T, Thalinger K, Hertzberg V. Hypertension as a risk factor for spontenous intracerebral hemorrhage. Stroke. 1986;17:1078–83.PubMedCrossRefGoogle Scholar
  42. 42.
    Brott T, Broderick J, Korthari R, et al. Early hemorrhage growth in patients with intracerebral hemorrhage. Stroke. 1997;28:1–5.PubMedCrossRefGoogle Scholar
  43. 43.
    Olson JD. Mechanisms of hemeostasis: effect of intracerebral hemorrhage. Stroke. 1993;24:1109–14.Google Scholar
  44. 44.
    Anderson CS, Huang Y, Wang JG, et al. Intensive blood pressure reduction in acute cerebral hemorrhage trial (INTERACT): a randomized pilot trial. Lancet Neurol. 2008;7:391–9.PubMedCrossRefGoogle Scholar
  45. 45.
    •• ATACH Investigators. Antihypertensive Treatment of Acute Cerebral Hemorrhage (ATACH). Crit Care Med. 2010;38:637–48. This trial compared BP targets in acute intracerebral hemorrhage but did not demonstrate any clinical differences in outcomes between the groups. CrossRefGoogle Scholar
  46. 46.
    Zhang Y, Reilly KH, Tong W, et al. Blood pressure and clinical outcomes among patients with acute stroke in Inner Mongolia, China. J Hypertens. 2008;26:1446–52.PubMedCrossRefGoogle Scholar
  47. 47.
    Wilmot M, Leonardi-Bee J, Bath PM. High blood pressure in acute stroke and subsequent outcome: a systemic review. Hypertension. 2004;43:18–24.CrossRefGoogle Scholar
  48. 48.
    Morgenstern LB, Hemphill JC, Anderson C, on behalf of the American Heart Association Stroke Council and Council on Cardiovascular Nursing, et al. Guidelines for the management of spontaneous intracerebral hemorrhage: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2010;41:2108–29.PubMedCrossRefGoogle Scholar
  49. 49.
    Teunissen LL, Rinkel GJ, Algra A, et al. Risk factors for subarachnoid hemorrhage—a systemic review. Stroke. 1996;27:544–59.PubMedCrossRefGoogle Scholar
  50. 50.
    Ingall TJ, Whisnant JP, Wiebers DO, et al. Has there been a decline in subarachnoid hemorrhage mortality? Stroke. 1989;20:718–24.PubMedCrossRefGoogle Scholar
  51. 51.
    Manno EM. Subarachnoid hemorrhage. Neurol Clin N Am. 2004;22:347–66.Google Scholar
  52. 52.
    Ohkuma H, Tsuratani H, Suzuki S. Incidence and significance of early aneursysmal rebleeding before neurosurgical or neurological management. Stroke. 2001;32:1176–80.PubMedCrossRefGoogle Scholar
  53. 53.
    Wijdicks EF, Vermeulen M, Murray GD, et al. The effects of treating hypertension following aneurysmal subarachnoid hemorrhage. Clin Neurol Neurosurg. 1990;92:111–7.PubMedCrossRefGoogle Scholar
  54. 54.
    •• Bederson JB, Sander-Connolly ES, Batjer HH, et al. Guidelines for the management of aneurysmal subarachnoid hemorrhage a statement for healthcare professionals from a special Writing Group of the Stroke Council, American Heart Association. Stroke. 2009;40:994–1025. This is the most recent guideline from the AHA regarding the treatment of patients with aneurysmal subarachnoid hemorrhage and should be mandatory reading for all who care for such patients. PubMedCrossRefGoogle Scholar
  55. 55.
    Matsuda M, Watanabe K, Saito A, et al. Circumstances, activities and events precipitating aneurysmal subarachnoid hemorrhage. J Stroke Cerebrovasc Dis. 2007;16:25–9.PubMedCrossRefGoogle Scholar
  56. 56.
    Anda T, Yonekura M, Baba H, et al. Factors affecting rapid growth of unruptured cerebral aneurysms during the acute stage of subarachnoid hemorrhage. Neurol Res. 2006;28:165–71.PubMedCrossRefGoogle Scholar
  57. 57.
    Juvela S. Prehemorrhage risk factors for fatal intracranial aneurysm rupture. Stroke. 2003;34:1852–7.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  1. 1.New York Presbyterian HospitalWeill Cornell Medical CollegeNew YorkUSA

Personalised recommendations